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1.  Introduction  
Article 5.1 of Council Decision 2005/387/JHA (1) (hereinafter referred to as the 
‘Decision’) stipulates that ‘Where Europol and the EMCDDA, or the Council, acting by 
a majority of its members, consider that the information provided by the Member 
State on a new psychoactive substance merits the collection of further information, 
this information shall be collated and presented by Europol and the EMCDDA in the 
form of a Joint Report (hereinafter the ‘Joint Report’).’ The Joint Report shall be 
submitted to the Council, the European Medicines Agency (EMA) and the European 
Commission. 
At the end of September 2013, the EMCDDA and Europol examined the available 
information on a new psychoactive substance 2-(3-methoxyphenyl)-2-
(ethylamino)cyclohexanone, commonly known by the short name ‘methoxetamine’, 
through a joint assessment based upon the following criteria: 
1. the amount of the material seized; 
2. evidence of organised crime involvement; 
3. evidence of international trafficking; 
4. analogy with better-studied compounds; 
5. evidence of the potential for further (rapid) spread; and, 
6. evidence of cases of serious intoxication or fatalities. 
The EMCDDA and Europol agreed that the information collected on methoxetamine 
satisfied criteria 1, 3, 4 and 6. The two organisations therefore concluded that 
sufficient information had been accumulated to merit the production of a Joint Report 
on methoxetamine as stipulated by Article 5.1 of the Decision. 
2. Information collection process 
In compliance with the provisions of the Decision, on 7 October 2013 the EMCDDA 
and Europol launched a procedure for the collection of information on 
methoxetamine, in order to prepare the Joint Report. The information was collected 
mainly through the Reitox National Focal Points in the Member States, Turkey and 
Norway as well as the Europol National Units. In addition, the EMA collected 
information through the national competent authorities responsible for human and 
veterinary medicinal products in the Member States as well as in Norway and 
Iceland. The information collection process was largely concluded by 18 November 
2013; however, additional information and clarifications from some countries were 
received up to four weeks after this date. 
 
(1) OJ L 127, 20.5.2005, p. 32. 
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Europol asked the Europol National Units to provide information on: 
• the level of production of methoxetamine in their country; 
• the level of distribution of methoxetamine in their country; 
• the level of trafficking of methoxetamine in their country, both for internal, 
transit or export purposes; 
• the number of seizures of methoxetamine in their country, the total amount of 
the seizures, country of origin, details on the physical forms (including 
photos); 
• the role of organised crime, or criminal groups, in the production, distribution 
and trafficking of methoxetamine in their country; and, 
• any known aspect of violence and/or money laundering relating to the 
production and trafficking of methoxetamine. 
Europol received responses from 15 Member States. 
According to Article 5.3 of the Decision, the EMA asked national competent 
authorities responsible for human and veterinary medicinal products in the Member 
States as well as Norway and Iceland to provide information on whether: 
• the new psychoactive substance methoxetamine has obtained a marketing 
authorisation; 
• the new psychoactive substance methoxetamine is the subject of an 
application for a marketing authorisation; and, 
• a marketing authorisation that had been granted in respect of the new 
psychoactive substance methoxetamine has been suspended. 
Twenty-four Member States (2), Norway and Iceland replied to the EMA’s request 
regarding human and/or veterinary medicinal products. The EMA also provided 
information as relevant to the central authorisation procedure. 
Furthermore, in anticipation of Article 7.3 of the Decision in relation to the 
manufacturing of medicinal products in the European Union, the EMA also requested 
whether the new psychoactive substance methoxetamine is used to manufacture a 
medicinal product: 
• which has been granted a marketing authorisation; 
• for which an application has been made for a marketing authorisation; and, 
 
(2)  Austria, Belgium, Croatia, Cyprus, Czech Republic, Denmark, Estonia, France, Germany, 
Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Malta, Netherlands, Poland, Portugal, 
Slovakia, Slovenia, Spain, Sweden, and the United Kingdom. 
5 
• for which a marketing authorisation has been suspended by a competent 
authority. 
Twenty-three Member States (3), Norway and Iceland replied to the EMA’s request in 
this regard. The EMA also provided information as relevant to the central 
authorisation procedure. 
The EMCDDA collected data through: 
1. a structured questionnaire from the Reitox National Focal Points. The EMCDDA 
received replies from 28 Member States as well as from Turkey and Norway; 
2. data previously provided to the EU Early Warning System in EMCDDA-Europol 
Reporting Forms, EWS Progress and Final Reports;  
3. a specific information request to the World Health Organization on whether or not 
methoxetamine is under assessment by the United Nations system (see section 
3.5), and; 
4. a structured search of the scientific literature and of relevant Internet sites. 
Thus, information included in sections 3.2.1 and 3.3 of the Joint Report was provided 
by Europol, while the EMCDDA provided information included in sections 3.1, 3.2.2, 
3.4, 3.5, 3.6, 3.7, 3.8.1, 3.8.2 and 3.8.3 (in part). The information included in sections 
3.8.3 (in part), 4.1, 4.2 and 4.3 was provided by the EMA. The conclusion of the Joint 
Report were prepared and agreed by the two organisations responsible — the 
EMCDDA and Europol. Further details of the seizures and collected samples 
(including images where available) reported to the EMCDDA are provided in Annex 
1. The details of non-fatal intoxications and deaths associated with methoxetamine 
that have been reported to the EMCDDA are provided in Annex 2. 
3.  Information required by Article 5.2 of the Decision 
The order and titles of subsections 3.1 to 3.8 and section 4 below are as they appear 
in Article 5.2(a) to (h) and Article 5.3(a) to (c) of the Decision; all sections are cross-
referenced with those set down in the Decision. 
 
(3)  Austria, Belgium, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Germany, Greece, 
Hungary, Ireland, Italy, Latvia, Lithuania, Malta, Netherlands, Poland, Portugal, Slovakia, 
Slovenia, Spain, Sweden, and the United Kingdom. 
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3.1 Chemical and physical description, including the names under which 
the new psychoactive substance is known — Article 5.2(a) of the 
Decision 
 
Chemical description and names 
 
Methoxetamine is an arylcyclohexylamine substance which shares some structural 
similarities to the dissociative anaesthetic drug ketamine. In methoxetamine, the 2-
chloro group on the phenyl ring and the N-methylamino group of ketamine have been 
replaced by a 3-methoxy and N-ethylamino groups respectively (Figure 1).  
  
The systematic chemical name for methoxetamine is (RS)2-(3-methoxyphenyl)-2-
(ethylamino)cyclohexanone. 
 
Additional chemical synonyms reported are: 
 
2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone; 
2-(3-methoxy-phenyl)-2-(ethylamino)-ciklohexanone; 
2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one;  
(2-(ethylamino)-2(3-methoxyphenyl)cyclohexan-1-one); 
(RS)2-(3-metoksifenyyli)-2-(etyyliamino)sykloheksanoni (Finnish); 
methoxyphenylethylamino-ketocyclohexane. 
 
Common names or codenames that have also been reported are: 3-MeO-2-Oxo-
PCE, MXE, MXE100 and metoksetamiini (Finnish). 
 
The following street names have also been reported: ‘MXE’, ‘Mexxy’, ‘M-ket’, ‘MEX’, 
‘Kmax’,  ‘Special M’, ‘MA’, ‘legal ketamine’, ‘Minx’, ‘Jipper’ and ‘Roflcoptr’. 
 
Finally, the following ‘legal high’ product names have been associated with 
methoxetamine: ‘Kwasqik’, ‘Hypnotic’, ‘Panoramix’, ‘Magic’, ‘Lotus’, ‘Special K’ and 
‘X’. 
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Figure 1. The numbered molecular structure, formula, weight and monoisotopic 
mass of methoxetamine. The molecular structure for ketamine is provided for 
comparison. 
 
  
Methoxetamine Ketamine 
Molecular formula:       C15H21NO2 
 
Molecular weight:         247.33 
 
Monoisotopic mass:     247.157 
 
 
Chemical Abstract Service registry numbers (CAS RN) 
 
1239943-76-0  free base 
1239908-48-5  hydrochloride salt 
 
The REACH registered substances database hosted by the European Chemicals 
Agency (ECHA) was searched using the CAS registry numbers listed above. The 
search returned no results. 
 
Physical description  
 
The hydrochloride salt of methoxetamine is a crystalline powder at room 
temperature. A physical description of the freebase form could not be found in readily 
accessible literature. An Internet search conducted by the EMCDDA reported that 
methoxetamine is offered for sale in free base and hydrochloride salt forms. The 
forms in which methoxetamine have been encountered in seizures and collected 
samples have not been specified by any country. 
 
Information provided from seizures and collected samples have noted the presence 
of methoxetamine in powders, powder-filled capsules, tablets, liquids and plant 
material. 
 
A more detailed description of methoxetamine seizures and collected samples that 
have been reported can be found in subsections 3.2.1 and 3.2.2 below.  
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3.2  Information on the frequency, circumstances and/or quantities in which 
a new psychoactive substance is encountered, and information on the 
means and methods of manufacture of the new psychoactive substance 
— Article 5.2(b) of the Decision 
3.2.1 Information provided to Europol 
Europol received replies from 15 Member States (Belgium, Bulgaria, Croatia, Cyprus, 
Denmark, Estonia, Finland, Hungary, Italy, Latvia, Lithuania, Luxembourg, Poland, 
Slovakia and Slovenia). Of these, seven countries had no data relating to 
methoxetamine (Bulgaria, Cyprus, Estonia, Italy, Latvia, Luxembourg, and Slovenia). 
The remaining eight countries (Belgium, Croatia, Finland, Germany, Hungary, 
Lithuania, Poland and Slovakia) reported the following information. 
The level of production, distribution and trafficking 
Belgium reported that methoxetamine had been seized on two occasions: once in 
2012, when the substance came from China and was destined to Italy (510 grams 
labelled as ZEOLITE; and once in 2013, when methoxetamine came from China 
again and was destined for Spain, 93 grams labelled as ULTRAVIOLET. 
Croatia provided information that methoxetamine appeared in three cases (2 grams 
in total). 
Finland reported 35 seizures in powder form (323.8 g in total). They also noted that 
as the use of ketamine in Finland is at a very low level there is limited demand for 
substitutes like methoxetamine. 
Germany reported 41 seizures that were made between December 2011 to July 
2013. The seizures ranged from 0.06 grams to 39.10 grams. The information 
provided indicated that either methoxetamine was identified as a single product or as 
mixture with other substances: MDPV, AM-2201, 4-fluoramphetamine and 3-FMC. In 
2013, methoxetamine was identified in mixtures with caffeine, taurine, 
methiopropamine and camfetamine. In some seizures methoxetamine was labelled 
with different names: “Xtreme White”, "methoxyphenylethylamino-ketocyclohexane" - 
"Warning: Research Use Only", "NOT FOR HUMAN CONSUMPTION", 2-
Naphthoxyacetic Acid, "Sodium Formate", "N-Ethyl-Ketamin" and "Methoxydin". 
Germany also reported details of an investigation that focused on online shop 
operators, which resulted in the seizure of more than 30 kg of new psychoactive 
substances with 39 different active agents identified. The methoxetamine that was 
identified among these active ingredients was labelled as methoxetamine and N-
Ethyl-Ketamine. Moreover, as part of this investigation police seized two capsule 
filling machines, 2500 empty capsules, cannabis, cash and several new psychoactive 
substances. Further checks have revealed that suspects ordered several new 
psychoactive substances via the Internet from Switzerland. These include: 
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methoxetamine, MDPV, 2C-E, 2C-P, 2-DPMP, 2-FA, 3,4-DMMC, 4-AcO-DiPT, 4-HO-
MIPT and 4-MEC.  
Hungary reported that seizures of methoxetamine had been made in tablet and 
powder form since 2011. Significant seizures of methoxetamine tablets (1890 in total) 
were reported in 2011. 
Lithuania recorded one seizure of 0.133 grams of methoxetamine in 2012. 
Poland reported three seizures of methoxetamine all in the form of a white powder 
(0.25 grams to 1.07 grams).  
Slovakia reported seven seizures as white or beige powder as well as capsules. The 
seizures ranged from 1.27 g to 643.91 g. The capsules have been reported in three 
seizures and had two different names: “Magic Hypnotic” (two of the seizures) and 
“PANORAMIX”.  
No reports were received that indicated licit or illicit production of methoxetamine in 
any of these countries.  
3.2.2  Information provided to the EMCDDA 
 
Twenty-two Member States (Austria, Belgium, Bulgaria, Croatia, Cyprus, Denmark, 
Estonia, Finland, France, Germany, Hungary, Ireland, Italy, Latvia, the Netherlands, 
Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, and the United Kingdom) and 
Turkey and Norway, reported detections of methoxetamine (4). 
Methoxetamine has been typically encountered in powder form. In most cases, it is 
reported as the only active substance present. In approximately 15 % of detections it 
was found in combination with other compounds, including phenethylamines (e.g. 4-
fluoroamphetamine in 20 cases), other synthetic cathinones (e.g. 4-MEC and/or 
MDPV in about 20 cases; mephedrone and/or methylone in 9 cases; 3,4-DMMC in 6 
cases; 4-FMC in 5 cases), synthetic cannabinoids (e.g. AM-2201, 4 cases; JWH-018, 
2 cases), other substances (e.g. 6-APB in 4 cases; 2-DPMP, 4 cases; 
methiopropamine/MPA, 3 cases; 3-MeO-PCP, 3 cases), benzodiazepines, 
methylphenidate, tryptamines, etc. It has been also encountered with ketamine and 
internationally controlled substances such as amphetamine, methamphetamine, 
MDMA, cannabis, morphine and heroin. In some of the samples, caffeine was also 
present. 
 
(4) ‘Detections’ is an all-encompassing term and may include seizures and/or collected and/or 
biological samples. Seizure means a substance available (seized) through law enforcement 
activities (police, customs, border guards, etc.). Collected samples are those that are actively 
collected by drug monitoring systems (such as test purchases) for monitoring and research 
purposes. Biological samples are those from human body fluids (urine, blood, etc.) and/or 
specimens (tissues, hair, etc.)  
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The available information strongly suggests that methoxetamine is sold both as a 
‘legal’ replacement for ketamine and on the illicit drug market as ketamine. In the 
latter case, users are unlikely to be aware of this. 
Seizures  
Twenty-two Member States (Austria, Belgium, Bulgaria, Croatia, Cyprus, Denmark, 
Estonia, Finland, France, Germany, Hungary, Ireland, Italy, Latvia, the Netherlands, 
Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, and the United Kingdom) and 
Turkey and Norway reported seizures of methoxetamine. Eight countries reported 
more than 40 seizures of methoxetamine: United Kingdom (640 seizures), Finland 
(252), Spain (76), Hungary (74), Norway (50), Poland (46), Germany (45) and France 
(43). In most of the countries, a large proportion of the seizures were small amounts 
of powder.  
Methoxetamine has typically been seized as a powder. Quantities of powders seized 
ranged from 0.01 grams to 15.5 kilograms (Hungary). In 2011, Hungarian customs 
reported four single seizures above 5 kilograms each, amounting to a total of more 
than 40 kilograms, and Italy reported one seizure above 4 kilograms from June 2011. 
There are also over 50 reports of seizures of tablets (about 10 % of cases, up to 
2800 units, Norway), twelve seizures of capsules containing powder (up to 173 units, 
Germany) and four seizures of liquids (up to 10 ml, United Kingdom). Methoxetamine 
was detected on injecting equipment in 13 occasions in Hungary (2011), and twice in 
Poland; in these cases, methoxetamine or traces of it were typically detected in 
combination with opioids or synthetic cathinones. 
In the United Kingdom, aggregated data on methoxetamine seizures (5) indicate that 
over 14 kilograms of methoxetamine powder have been seized since 2011. Finland 
(customs, 242 seizures; police, 10 seizures) reported most of the seizures in powder 
form (from 0.01 to 248.7 grams), amounting to a total of 810 grams, since December 
2010. Spain reported 76 seizures of powder amounting to a total of 1.4 kilograms. 
Hungary reported two thirds of the seizures in powder (amounting to a total of 41.8 
kilograms) and one third of seizures of tablets (from 1 to 500 units). Of the tablets, 
80% contained 3- or 4-fluoroamphetamine alone or in combination mostly with 
synthetic cathinones (pentedrone, 4-FMC, 4-MEC, MDPV, methylone), synthetic 
cannabinoids (AM-2201) or 6-APB. Norway reported 50 seizures, including 6 
seizures of capsules containing powder (from 1 to 200 units) and 9 seizures of 
tablets (from 1 to 2800 units) since September 2011. Poland reported small seizures 
of powder (from 0.05 to 62.5 grams), three seizures of tablets (from 2 to 10 units), 
and 1 capsule containing powder (5 units). In two cases, traces of methoxetamine 
were found in a metal spoon in combination with other substances, including 
morphine, papaverine, codeine, and thebaine in one case, and morphine, heroin, 
 
(5)  Many ‘seizures’ relate to individual case-level data, however, some data provided to the 
EMCDDA are aggregated at the country level. Some of the data from the United Kingdom are 
reported as ‘records’, where several records may have come from the same case. Data is 
drawn from the Joint report questionnaires and data provided in the bi-annual data gathering 
and from individual reporting forms submitted on an ad hoc basis. 
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acetylcodeine and 6-MAM in the other case. In Germany, a seizure of 173 capsules 
and a range of powders seized in small quantities (from 0.63 to 39.1 grams) were 
reported, including products seized from an online shop labeled as ‘methoxetamine’ 
and ‘N-Ethyl-Ketamin’. In France, small quantities of powder were seized, including a 
single seizure of 500 grams of methoxetamine seized by customs at the Roissy 
airport (Paris). 
Six countries reported between 5 and 20 seizures of methoxetamine: Netherlands 
(18), Sweden (17, with the biggest single seizures amounting to 289 grams of 
powder and 72 tablets), Italy (13, one of which was 4.36 kilograms), Austria and 
Denmark (9 small seizures of powder each), Slovakia (7, the two biggest ones 
consisting of 330 and 643 grams). A small number of seizures were reported in 
Bulgaria, Croatia, Cyprus, Estonia, Ireland, Latvia, Portugal and Slovenia. Belgium 
reported two seizures from customs at Bierset airport (Liége), one of which from 
China; Turkey reported one seizure in the form of light green plants, which also 
contained the synthetic cannabinoids JWH-122 and AM-2021.  
Biological samples 
Eight Member States reported biological detections of methoxetamine.  
Four countries (Belgium, France, Italy and Sweden) reported a total of 54 analytically 
confirmed non-fatal intoxications (Belgium, 1 case; France, 3; Italy, 12; Sweden, 38). 
Not all of these were analytically confirmed. 
Six Member States reported a total of 20 deaths: Austria (1 case), Finland (1), 
France (1), Poland (1), Sweden (1) and the United Kingdom (15). 
Sweden reported 17 detections (5 in blood; 12 in urine) related to individuals 
suspected of committing a minor criminal offence. The United Kingdom reported one 
detection related to a case of suspected driving under the influence of drugs. 
See section 3.4.1 and Annex 2 for further details of the non-fatal intoxications and 
deaths associated with methoxetamine. 
Collected samples  
In addition to the detections of methoxetamine in seizures and biological samples, 
eight Member States (Austria, Belgium, France, Hungary, Italy, the Netherlands, 
Slovakia, the United Kingdom) also reported collected samples of methoxetamine.  
In Austria, between July 2012 and February 2013 the ‘pill’-testing project run by 
‘ChEckiT!’ detected methoxetamine in samples collected in Vienna. There were 4 
tablets (containing between 19 to 73 mg of methoxetamine) and six samples of 
powder (with methoxetamine concentration ranging from 7 mg/g to 980 mg/g). The 
samples were sold at user level as methoxetamine (4 cases), ecstasy (4), MDMA (1) 
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and speed (1). In one of the samples, amphetamine (66 mg/g) and caffeine (179 
mg/g) were also detected.  
Belgium reported the analysis of one gram of powder related to the non-fatal 
intoxication described below which was found on the patient. 
France reported 21 samples of powder collected from different venues by the 
SINTES surveillance system (16 samples collected between July 2011 and July 
2013) and the Observatoire Français des Drogues et des Toxicomanies (OFDT) (5 
samples collected in 2013) (6). In about half of the samples collected by SINTES the 
methoxetamine had been sold as ketamine. No quantitative information is available 
for any of the 21 samples. 
Hungary reported a sample of powder collected for the purpose of analysis which 
was found to contain methoxetamine. 
Italy reported three samples of powder ranging in weight from 0.63 grams to 5 grams 
(sample related to a non-fatal intoxication described in Section 3.4.1) and one 
sample of liquid (7). No other substances were detected in addition to 
methoxetamine.  
In the Netherlands, the Drugs Information and Monitoring System (DIMS) detected 
methoxetamine tablets in two cases in 2011 (7) and powders in 21 cases in 2012 and 
in seven cases in 2013. In all the cases it was sold as either methoxetamine or 
ketamine. 
Slovakia reported three ‘legal high’ products offered online as capsules or powder 
and branded ‘Hypnotic’, ‘Panoramix’ and ‘Magic’. 
The United Kingdom reported a sample of methoxetamine purchased from an 
Internet retailer (buyresearchchemical.co.uk) in September 2010. The product, 
labelled ‘Methoxetamine’, contained 250 mg of white powder which was found to be 
high purity methoxetamine. This sample formed the basis of the first notification of 
detection of methoxetamine in the European Union (see section 3.6). 
Further details of these collected samples, including information on the product 
labels, are provided in Annex 1. 
 
(6)  Subjective effects reported include: ketamine-like but more aggressive at the same dose; teeth 
pain when using sublingual route of administration; one convulsion followed by coma and 
hospitalisation for 96 hours and psychological effects including paranoia, panic attack, black 
out and depression. 
(7) Data reported in EMCDDA-Europol Reporting Forms and biannual EWS progress and final 
reports. 
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3.3 Information on the involvement of organised crime in the manufacture 
or trafficking of the new psychoactive substance — Article 5.2(c) of the 
Decision 
Germany reported that there are no links to suggest the involvement of organised 
crime groups in the production, trafficking and/or distribution of methoxetamine. They 
also noted that it should be borne in mind that easy access to substances in and 
outside of the European Union (also in big amounts) via Internet shops indicates at 
least a certain level of organisation. In addition, the interest and presence of 
organised crime groups in the phenomenon of new psychoactive substances can be 
easily concluded from enormous attainable financial profits they can obtain from this 
type of criminal activities.   
Money laundering aspects 
No information was received on money laundering connected to the production 
and/or trafficking of methoxetamine. 
Violence in connection with production, wholesale and distribution 
No information was received on incidents of violence in connection with the 
production, wholesale and/or trafficking of methoxetamine. 
3.4 A first indication of the risks associated with the new psychoactive 
substance, including the health and social risks, and of the 
characteristics of users — Article 5.2(d) of the Decision   
3.4.1 First indication of health risks 
A total of 110 non-fatal intoxications and 20 deaths associated with methoxetamine 
were reported by eight Member States (Austria, Belgium, Finland, France, Italy, 
Poland, Sweden and the United Kingdom). Not all of these cases have been 
analytically confirmed. 
Non-fatal intoxications  
Belgium  
Belgium reported two non-fatal intoxications. The first case occurred in October 
2011. The patient contacted the Belgian Poison Centre and complained about 
dizziness after taking methoxetamine. This case was not analytically confirmed. In 
the second case, from October 2013, the patient reported experiencing hallucinations 
and dissociation after taking an unspecified amount of powder sold as ‘Special K’ (a 
street name for ketamine). The presence of methoxetamine was analytically 
confirmed in a urine sample as well as in a sample of the powder that had been 
consumed by the patient. Reported symptoms were: mydriasis, black outs, 
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confusion, vertigo, insomnia, lowered consciousness, and cardiac and respiratory 
depression. 
France 
France reported three non-fatal intoxications. In one case the methoxetamine was 
quantified as 30 µg/L in plasma and 408 µg/L in urine; in another the methoxetamine 
was quantified as 136 ng/mL in plasma (cannabis and acetaminophen were also 
detected); while in a third case methoxetamine was detected in a sample of hair. No 
further details are available at this time (8). 
Italy 
Italy provided detailed reports for 14 non-fatal intoxications which occurred between 
March 2011 and July 2013 (1 case in 2011; 9 in 2012; and, 4 in 2013). Twelve of the 
cases were analytically confirmed. The first case, which was not analytically 
confirmed is described as an example. The patient reported having ordered ketamine 
via the Internet and then instead of the expected substance, a package of powder 
labelled as methoxetamine arrived. The patient dissolved the powder in water and 
injected the solution and then ‘experienced panic, anxiety, hallucinations and feelings 
clearly different from those expected … with the use of ketamine’, so then called the 
emergency service to be taken to hospital. In the other case without analytical 
confirmation, the patient reported being given methoxetamine powder by a friend 
which was taken nasally. The remaining cases were all confirmed analytically and 
further details are provided in Annex 2. The levels of methoxetamine are provided for 
three of the cases. Where information is provided on the substance taken, five of the 
patients reported having taken ketamine which was detected in just two of those 
cases. In two further cases, the patients reported having taken methoxetamine. Two 
patients reported taking an unknown powder. In six cases the patients had attended 
dance or rave parties.  
All analyses conducted revealed the presence of methoxetamine with other 
substances in the following frequencies: alcohol (5 cases), cannabis (finding of THC) 
(5), amphetamines (4), MDMA (4), cocaine (3), ketamine (2), APB (9) isomers (2), 
levamisole (2), opiates (1), MDA (10) (1), methorphan (1), buprenorphine (1) and 
methadone (1).  
Adverse observed effects included: agitation (7 cases), confusion (5), hallucinations 
(4), amnesia (3), dissociation (1), anxiety (1), disorientation (1), violence (1). 
Furthermore, physiological symptoms were reported: mydriasis (4 cases), mild 
 
(8)  France also reported nine cases through the Centres d'Evaluation et d'information sur la 
Pharmacodépendance (CEIP) on the unique basis on patient's interview. These nine patients 
had requested medical support after using what they thought to be methoxetamine but its 
presence was not analytically confirmed, either in blood sample neither in a drug sample. In 
some cases the methoxetamine had been purchased from the Internet. 
(9) (Aminopropyl)benzofuran 
(10) 3,4-Methylenedioxyamphetamine 
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hypertension (4), tachycardia (4), unresponsive (2) stupor (2, one of which was 
catatonic at times), oxygen saturation of 90% (1) coma (1), chest pain (1), elevated 
creatine phosphokinase (CPK) (1) and tremors (1). Several of the case reports 
mentioned the absence of elevated temperature. 
Sweden 
Sweden reported 91 non-fatal intoxications between March 2011 and January 2013. 
Further information was provided for 38 cases that were analytically confirmed that 
were part of a larger case series of 71 cases of suspected methoxetamine 
intoxication (see Section 3.4.2 and Annex 2 for further details). 
Methoxetamine was the only substance detected in 11 of these cases. In these 
cases, the following symptoms were noted: hypertension (4), tachycardia (4), 
hallucinations (3), nystagmus (3), CNS-depression (3), mydriasis (3), anxiety (3), 
muscular symptoms (2) and agitation/restlessness (1). The Poison Severity Scores 
(Persson et al., 1998) reported for these cases were PSS 1-mild (7 cases), PSS 2-
moderate (2) and PSS 3-severe (2).The two cases of severe poisoning presented  
unconscious, one of them with respiratory depression. A mixed poisoning in the latter 
case, cannot be ruled out as a urine sample was not available. (Östberg et al, 2013). 
Deaths 
Austria 
Austria reported one death that occurred in August 2012. The cause of death was 
reported as central circulatory failure due to methoxetamine overdose. No further 
details were provided. 
Finland 
Finland reported one death that occurred in August 2012. The case related to a 
drowning. Methoxetamine was detected in blood at a concentration of 5200 mg/mL. 
Other substances detected were olanzapine (0.24 mg/mL); citalopram (0.20 mg/mL) 
and clozapine (0.13 mg/mL). 
France 
France reported one death that occurred in February 2013. The deceased was found 
dead at home. The cause of death was reported as asphyxia. Methoxetamine was 
detected in blood at a concentration of 9.48 µg/mL. The drug was in a powder form 
and the route of administration was oral or nasal. The results of toxicological analysis 
for other substances detected only benzodiazepines that are believed to be from 
hospital treatment. 
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Poland 
Poland reported one death that occurred in July 2012. The cause of death was 
reported as acute poisoning as a result of methoxetamine and amphetamine. The 
methoxetamine had been bought via the Internet. It was taken nasally. It was 
believed that ‘2-CB’ (1 "stamp" saturated with 100-120 µg), amphetamine and 
‘hashish’ had also been taken. Toxicological analyses revealed methoxetamine in 
blood (0.32 µg/mL) and urine (4.36 µg/mL). No methoxetamine was detected in the 
hair. Amphetamine was present in blood (0.06 µg/mL), urine (0.27 µg/mL) and hair 
(0.19 µg/g). The patient was taken to hospital in a very poor general condition. He 
was in a deep coma, with clinical and biochemical features of acute respiratory 
failure, hyperthermia (>39°C) and generalized seizures. Laboratory tests showed 
elevated leukocytosis, signs of massive rhabdomyolysis and acute renal and hepatic 
failure. Despite intensive therapy the patient died 28 days later as a result of multiple 
organ failure. 
Sweden 
Sweden reported one death which occurred in February 2012. Methoxetamine was 
detected in post-mortem femoral blood at a concentration of 8.6 µg/g. The synthetic 
cannabinoids AM-694, AM-2201, and JWH-018, cannabis and venlafaxine were also 
detected. The cause of death was suspected to be acute intoxication with 
methoxetamine although the presence of the three synthetic cannabinoids may have 
contributed to the death (Wikström et al., 2012). 
United Kingdom 
The United Kingdom reported a total of 15 deaths that occurred between 2011 
(month not reported) and January 2013 (2 cases in 2011, 12 in 2012 and 1 in 2013). 
In one of the cases from 2011, the deceased was found decomposed at home and 
the cause of death was not provided. Additional substances that were detected post-
mortem were fluoromethcathinone, MDMA, methylone, MDAI (11), 5-IAI (12), MDPV, 
and AMT (13). The causes of death were provided for eight cases as: acute 
intoxication (4 deaths), drowning (3), natural causes (1). In the cases of acute 
intoxication, methoxetamine was not the only substance detected. One case involved 
6-APB (14), another methylthienylpropamine (MPA), in another case methadone, 
mirtazapine were implicated in the death and the final case of mixed drug toxicity 
also contained cocaine, ecstasy, amitriptyline and diazepam. In one of the cases of 
drowning and two of the acute intoxications the concentrations of methoxetamine 
were reported (see Annex 2). In the remaining six cases no cause of death was 
reported. 
 
(11)  5,6-Methylenedioxy-2-aminoindane 
(12) 5-Iodo-2-aminoindane 
(13) Alpha-methyltryptamine 
(14)  6-(2-Aminopropyl)benzofuran 
17 
Additional details of the deaths associated with methoxetamine are provided in 
Annex 2. 
Pharmacology and mode of action 
Roth et al., (2013) examined the neuropharmacological profile of methoxetamine in 
vitro. Information was not provided on the enantiomeric composition of the 
methoxetamine that was used. The data suggests that methoxetamine has a sub-
micromolar affinity for the N-methyl-D-aspartate (NMDA) receptor that is comparable 
to or greater than ketamine. The specific NDMA receptor subtype was not 
distinguished. In addition methoxetamine appears to have a sub-micromolar affinity 
for SERT (the serotonin transporter) (Table 1). This is a property that methoxetamine 
shares with phencyclidine (PCP) but not ketamine (Roth et al., 2013). Metabolites of 
methoxetamine were not studied.  
Data on the possible metabolites and metabolic pathways for methoxetamine have 
been reported by Meyer et al., (2012) and Menzies et al., (2013). 
No studies were identified that have examined the pharmacology and mode of action 
of methoxetamine in humans.  
Table 1. Representative pKi values for methoxetamine, ketamine and 
phencyclidine. Key: “—” indicate that compounds failed the Primary Screen criterion 
of >50% inhibition at 10 mM. Abbreviations: NMDA (N-methyl-D-aspartate receptor); 
SERT (serotonin transporter); NET (norepinephrine transporter). Adapted from Roth 
et al., (2013). 
Compound NMDA pKi ± SD 
(Ki, nM) 
SERT pKi ± SD 
(Ki, nM) 
NET pKi ± 
SD (Ki, nM) 
Sigma1 pKi ± 
SD (Ki, nM) 
Sigma2 pKi ± SD 
(Ki, nM) 
Ketamine 6.18±0.07 (659) — — — — 
Methoxetamine 6.59±0.06 (259) 6.32±0.05 (481) — — — 
Phencyclidine 7.23±0.07 (59) 5.65±0.05 (2234) — — 6.82±0.09 (136) 
Toxicology 
No studies were identified that have examined the toxicity of methoxetamine in vitro. 
No studies were identified that have examined the acute toxicity of methoxetamine in 
animals. One study was identified that examined the potential for chronic toxicity of 
methoxetamine on the renal system and bladder of mice (Wood et al., 2012d; Yew et 
al., 2012). The study was undertaken to examine the claim made by retailers that 
methoxetamine is a ‘bladder friendly’ alternative to ketamine. Chronic use of 
ketamine is associated with serious toxicity of the renal system and bladder (Advisory 
Council on the Misuse of Drugs, 2013; Li et al., 2013; Morgan et al., 2012). Two-
month-old Institute of Cancer Research (ICR) mice were administered either 30 
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mg/kilograms of methoxetamine per day (n=5) or saline control (n=3) by 
intraperitoneal injection for three months. Hydropic degeneration in both the proximal 
and distal convoluted tubules of the kidney and inflammatory cell infiltration of the 
kidneys was seen in all the mice administered methoxetamine; glomerular atrophy 
was seen in three of these mice. Mononuclear cell infiltration in the submucosal layer 
and in the muscle layer of bladder was seen in all of the mice administered 
methoxetamine. None of the above histological changes were seen in mice 
administered the saline control. No studies were identified that have examined the 
toxicity of methoxetamine in humans. 
The clinical features of acute toxicity associated with methoxetamine use as reported 
by the Member States are provided in section 3.4.1 ‘non-fatal intoxications’ and 
Annex 2 (15). These include a number of analytically confirmed cases and in a subset 
of these methoxetamine was the only substance detected in the toxicology screen. 
Two case series from the United Kingdom were also identified in the literature which 
reports the details of a total of six analytically confirmed cases of acute intoxication 
associated with methoxetamine use (Shields et al., 2012; Wood et al., 2012b). The 
clinical features were similar to some of those reported by the Member States. These 
included ketamine-like dissociation and activation of the sympathetic nervous 
system. In addition, in three of the six cases the patients developed acute cerebellar 
toxicity (Shields et al., 2012). In these three cases, methoxetamine was the only 
substance detected in the toxicology screen. 
Methods for the toxicological screening for methoxetamine have been reported by De 
Paoli et al., (2013). 
Dependence and abuse potential 
No studies were identified that have examined the dependence and abuse potential 
of methoxetamine in vitro, in animals or in humans. 
Some self-reported experiences on user websites suggest compulsive re-dosing of 
methoxetamine as well as the unintentional consumption of more than was initially 
planned (e.g. Erowid, 2013a,b). 
3.4.2 Characteristics of users 
The section below includes a discussion of the characteristics of users which include 
self-reported use (including drug regimens and effects) from Internet drug discussion 
forums and related websites (hereafter ‘user websites’). This includes a 
phenomenological study by Kjellgren & Jonsson (2013) that draws on self-reported 
experiences on user websites. As such it is important to note that it is not possible to 
confirm the specific substance(s) used, nor the purity, dose, etc. Analysis of products 
 
(15) The study by Hill et al., (2013) provides additional information on the clinical characteristics and 
patterns of enquiries related to acute toxicity associated with methoxetamine that were reported 
to the National Poisons Information Service in the United Kingdom. These cases were not 
necessarily analytically confirmed. 
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containing new psychoactive substances that are sold on the drug market have 
shown that the composition can differ between that claimed by the retailer, as well as 
differ over different geographical areas and time.  In addition, the information 
provided by patients in case reports/series as well as that provided on user websites 
should be regarded as illustrative only and not taken as representative of users of 
methoxetamine in general. Finally, information from seizures and collected samples 
and user websites suggest that methoxetamine has been commonly sold as a ‘legal’ 
replacement for ketamine or sold as ketamine directly on the illicit drug market. In the 
latter case users may be unaware that they are using methoxetamine. Additional 
research is required in order to examine to what extent, if any, the characteristics of 
methoxetamine users overlap and/or reflect those who use ketamine. 
Route of administration, dose and drug regimens 
Information provided by the Member States, as well as from patients in case 
reports/series, and self-reports from user websites suggest the route of 
administration for methoxetamine include nasal insufflation (‘sniffing’ or ‘snorting’), 
oral (swallowed either as a solid, such as through ‘bombing’, or dissolved into a 
solution), rectal, intramuscular injection, and intravenous injection (Erowid, 2013; 
Google, 2013a; Google, 2013b; Kjellgren & Jonsson, 2013; Östberg et al., 2013; Sein 
et al., 2012; Shields et al., 2012; Westwell et al., 2013; Wood et al., 2012b). In one 
case series of 71 patients, half of which were aged under 26 years old, that were 
hospitalised after suspected methoxetamine intake, and in which 38 patients the use 
of methoxetamine was analytically confirmed in urine and/or serum, the route of 
administration was reported as oral (38%), nasal (37%), intramuscular/intravenous 
injection (7%), sublingual (4%), rectal (1%), unknown (13%) (Östberg et al., 2013).  
Kjellgren & Jonsson (2013) analysed 33 self-reported experiences of methoxetamine 
use from drug user sites where methoxetamine was the only substance (excluding 
tobacco) reported to be used (32 male; 1 female) found that the most common route 
of administration was nasal insufflation (64%), intramuscular injection (15%), sub-
lingual (12%) and oral (9%). Methoxetamine has also been detected in samples 
recovered from injecting equipment on 13 occasions in Hungary during 2011 and two 
occasions in Poland during once in 2012 (the date in the second case was not 
specified). In these cases methoxetamine was typically detected in combination with 
opioids or synthetic cathinones. 
An analysis of the 33 self-reported experiences of methoxetamine use from user 
websites, where methoxetamine was the only drug reported to be used at the time, 
found that the total amount of methoxetamine taken during the experiences ranged 
from 10 mg to 200 mg (n=29 reports; mean dose=88 mg). The amount taken by route 
of administration was not provided; Table 2 provides an indication of these (Kjellgren 
& Jonsson, 2013). Other information from user websites appear to be consistent with 
these doses although there is considerable variation therein depending on the length 
of the experience, route of administration, other drugs used, etc. (Erowid, 2013; 
Google 2013a; Google 2013b). 
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In respect of the doses reported by patients of non-fatal intoxications, Westwell et al., 
(2013) in their case report of a non-fatal intoxication from the United Kingdom 
reported that their patient initially insufflated 25 mg, a further 25 mg half an hour later, 
and ‘pleased with the initial effects’ approximately 950 mg. Wood et al., (2012b) in 
their case series of three non-fatal intoxications from the United Kingdom report that 
in one case the patient had snorted 0.5 g of methoxetamine, 0.75 g of “benzofury” 
and had drunk approximately 1.5 L of beer; while another patient had drunk 
approximately 200 mg of ‘methoxetamine powder’ which had been dissolved in 
water. Information was not provided in the third case. 
Information from user websites and case report/series suggest that methoxetamine 
may be used on its own as well as in combination with other new psychoactive 
substances and/or controlled drugs (Erowid, 2013; Google 2013a; Google 2013b; 
Kjellgren & Jonsson, 2013; Shields et al., 2012; Wood et al., 2012b). In addition in 
some of the cases of non-fatal intoxications and deaths provided by the Member 
States other new psychoactive substances and/or controlled drugs were detected in 
biological samples. 
Subjective effects 
No clinical trials were identified that have examined the subjective effects of 
methoxetamine in humans; information is largely limited to that provided in case 
reports/series and self-reported experiences from user websites (Erowid, 2013; 
Google 2013a; Google 2013b; Kjellgren & Jonsson, 2013; Shields et al., 2012; Ward 
et al., 2011; Westwell et al., 2012). These include dissociative (including 
depersonalization), hallucinogenic and stimulant-type effects. In some cases the 
dissociative effects of methoxetamine are described as being ketamine-like although 
user reports suggest they may last for a longer period of time (up to 24 hours) 
(Erowid, 2013; Google 2013a; Google 2013b). Table 2 provides an indication of the 
dosages, subjective effects and duration of effects based on an unspecified number 
of user reports from a user website (Erowid). (Kjellgren & Jonsson, 2013). 
Table 2. Comparison of dose, duration and effects between methoxetamine and 
ketamine based on user reports from Erowid. Details on the number of cases 
included were not provided. Adapted from Kjellgren & Jonsson (2013). 
 
Methoxetamine Ketamine 
Common dosage 
(recreational use) 
20–60 mg insufflated 
40–60 mg oral 
15–30 mg intramuscular 
30–75 mg insufflated 
75–300 mg oral 
25–50 mg intramuscular 
Duration 150–240 min insufflated 
180–300 min oral 
120–180 h intramuscular 
45–60 min insufflated 
60–120 min oral 
30–60 min intramuscular 
Positive effects euphoria 
sense of calm and serenity 
euphoria 
sense of calm and serenity 
Neutral effects distortion or loss of sensory 
perception 
distortion or loss of sensory 
perception 
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Methoxetamine Ketamine 
Negative effects severe dissociation, 
depersonalization, loss of 
consciousness, nausea, vomiting 
severe dissociation, 
depersonalization, loss of 
consciousness, nausea, vomiting 
Availability and supply 
Internet monitoring of online shops selling new psychoactive substances to 
consumers (conducted by the EMCCDA) as well as information from user websites 
suggest that while methoxetamine is sold, bought and used as a drug in its own right 
it is marketed as a ‘legal’ and ‘bladder friendly’ alternative to ketamine. In some 
cases it is used as a substitute for ketamine (EMCDDA 2011; EMCDDA 2012; 
Kjellgren & Jonsson, 2013; Morris, 2011). Reflecting this, analysis of products sold as 
‘legal highs’ and analytically confirmed as containing methoxetamine have in some 
cases been branded using the same street names used for ketamine such as 
‘Special K’ (EMCDDA, 2002; Wood et al., 2012a). Information provided by the 
Member States from collected samples supports this finding; in some cases 
methoxetamine has been sold to users directly on the illicit drugs market as ketamine 
as well as mescaline, ecstasy, MDMA, and ‘speed’. 
The Internet monitoring exercise also identified 14 online shops offering 
methoxetamine in January 2011, 58 in July 2011, and 68 in January 2012. The price 
in 2011 for 10 g ranged from 145 to 195EUR (EMCDDA, 2011; EMCCDA, 2012). It is 
important to note that the online sale of methoxetamine may have changed 
substantially between the date of the last data collection on methoxetamine in 
January 2012 and the time of writing the Joint Report in December 2013. In part this 
may reflect responses of retailers to national control measures that have been put in 
place in some countries. A search of google.com using the search string “buy 
"methoxetamine" OR “mxe"" conducted in December 2013 for the Joint Report 
identified a number of online shops offering methoxetamine for sale in both retail and 
wholesale quantities (Google, 2013c). 
Prevalence of use 
Data from prevalence surveys 
No prevalence surveys were identified that have examined the use of methoxetamine 
in the general population. Five targeted surveys were identified that have included 
questions on the use of methoxetamine. Four surveys examined use in the United 
Kingdom. One study examined use in the Netherlands; data from this study is not 
included here as the results are currently embargoed. Among other possible 
methodological limitations, targeted surveys tend to use non-probabilistic sampling. 
As such the findings cannot be generalised to other populations. In addition it is 
important to note that two of the surveys from the United Kingdom, reported by the 
2012 Global Drug Survey and Wood et al., (2012c), and some of the fieldwork for the 
survey conducted by Measham et al., (2012), were undertaken before 
methoxetamine was subject to a temporary control measure on 5 April 2012 making 
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it unlawful to supply, possess with intent to supply, produce, and import or export 
methoxetamine except under licence. Possession for personal use was lawful at this 
time until methoxetamine was brought under permanent control in the United 
Kingdom on 26 February 2013 (16). 
Wood et al., (2012c) surveyed a total of 315 individuals attending gay-friendly night 
clubs in South East London in July 2011 on their use of novel psychoactive 
substances, cocaine, MDMA/ecstasy. The majority were men 262 (82%), reflecting 
that the night clubs catered for the gay community, 45 (15%) were women and 3 
(1%) trans-gender (data only available for 310 participants). The mean age of 
respondents was 29.7 years (range: 18–59 years). 206 out of 313 (65.8%) individuals 
reported having previously used a ‘legal high’. Of these, 6.4% reported life-time use 
of methoxetamine; 1.9% reported use in the last month; 1.6% reported use on the 
night of the survey or planned to use it later that night.  
The online 2012 Global Drug Survey conducted in November 2011 reported that out 
of 7700 respondents from the United Kingdom, 4.2% reported using methoxetamine 
in the last year (6% of clubbers and 3% of non-clubbers) and 2.4% reported using 
methoxetamine in the previous month (4% of clubbers and 1% of non-clubbers). For 
comparison, 24.5% and 9.3% reported using ketamine in the previous year and 
previous month respectively (Advisory Council on the Misuse of Drugs, 2012; 
Rogers, 2012). 
A survey conducted in ten nightclubs on six fieldwork nights in March, April and June 
2012 by Measham et al., (2012) reported that out of 343 respondents, 3% had ever 
used methoxetamine, with 3% reporting use in the last year, 2% in the past month 
and 1% in the past week. It is unclear from this survey whether all the respondents 
reporting methoxetamine use had done so during the period when the majority of 
fieldwork was conducted in March 2012 and hence before methoxetamine was 
subject to temporary control measures on 5 April 2012. 
The online 2013 Global Drug Survey conducted towards the end of 2012 reported 
that the lifetime use of methoxetamine by clubbers in the United Kingdom was less 
than 3%. For comparison, 50.6% reported lifetime use ketamine (Mixmag, 2013). No 
further details on the sample size, etc., are available. The survey appears to have 
been conducted during the period that methoxetamine was subject to temporary 
control measures in the United Kingdom. 
Information from a range of sources suggests that methoxetamine is being sold as a 
‘legal’ replacement to ketamine and directly on the illicit drug market as ketamine. As 
such it may be relevant to consider the prevalence of ketamine use. Data from the 
2012/2013 Crime Survey for England and Wales (United Kingdom) reported that 
0.4% of adults aged 16 to 59 and 0.8% of young adults aged 16 to 24 reported use of 
ketamine in the last year (Home Office, 2013). 
 
(16) For further details see: https://www.gov.uk/government/publications/change-to-the-misuse-of-
drugs-act-1971 
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Data from pooled urine samples 
Archer et al., (2013) analysed samples of pooled urine collected from 12 portable 
urinals located in the City of Westminster, a borough in central London, United 
Kingdom. The borough had a variety of night-time economy venues including bars, 
late night cafes and nightclubs. The urinals were available for use by the general 
public over a 12 hour period between 18:00 and 06:00 on a Saturday night and 
Sunday morning in March 2012. The urinals were designed for men. Use of the 
urinals was anonymous. Methoxetamine and metabolites were detected in a sample 
taken from one urinal. For comparison, ketamine and metabolites were detected in a 
sample taken from six urinals. 
3.5 Information on whether or not the new substance is currently under 
assessment, or has been under assessment, by the UN system — 
Article 5.2(e) of the Decision 
The World Health Organization is the specialised United Nations agency designated 
for the evaluation of the medical, scientific and public health aspects of psychoactive 
substances under the Single Convention on Narcotic Drugs, 1961 and the 
Convention on Psychotropic Substances, 1971. On 10 October 2013, the World 
Health Organization informed the EMCDDA that methoxetamine is currently under 
assessment and ’the critical review report will be published only early next year 
(probably April)’.  
Article 7.1 of Council Decision states that ‘no risk assessment shall be carried out in 
the absence of a Europol/EMCDDA Joint Report. Nor shall a risk assessment be 
carried out where the new psychoactive substance concerned is at an advanced 
stage of assessment within the United Nations system, namely once the WHO expert 
committee on drug dependence has published its critical review together with a 
written recommendation, except where there is significant new information that is 
relevant in the framework of this Decision’. 
This Joint Report has been produced on the understanding that methoxetamine is 
not at an advanced stage of assessment within the United Nations system. 
3.6 The date of notification on the Reporting Form of the new psychoactive 
substance to the EMCDDA or to Europol — Article 5.2(f) of the Decision 
The first official EMCDDA–Europol notification of methoxetamine dates from 
November 2010 from the United Kingdom National Focal Point. The Reporting Form 
details a collected sample purchased from the internet (17) on 30 September 2010. 
The collected sample comprised a packet labelled ‘Methoxetamine’ containing 250 
milligrams of white powder. The report notes that it ‘appeared to be of high purity’. 
 
(17) Purchased from http://www.buyresearchchemical.co.uk  
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The identification was based on the analytical techniques of GC-MS (18) and NMR 
(19). 
Methoxetamine was added to the list of new psychoactive substances monitored by 
the EMCDDA and Europol through the European Union Early Warning System and a 
profile of the substance was created in the EMCDDA European Database on New 
Drugs (EDND). Analytical details and background information have been exchanged 
on various occasions between EMCDDA, Europol and the Member States. The 
European Commission and the EMA were kept duly informed. 
3.7 Information on whether or not the new psychoactive substance is 
already subject to control measures at national level in a Member State 
— Article 5.2(g) of the Decision 
Eight Member States (Cyprus, Denmark, France, Germany, Italy, Slovenia, Sweden, 
and the United Kingdom) and Turkey reported that methoxetamine is subject to 
control under drug control legislation.  
In Cyprus, methoxetamine was listed as covered by Cypriot drug control law by name 
in 2012. In Denmark methoxetamine is covered by the Executive Order on 
Euphoriant Substances. In France methoxetamine is added on the controlled narcotic 
substance list by the ordinance of 5 August 2013. In Germany methoxetamine is 
included in the list covered by the Narcotic Substance Law since 17 July 2013. In 
Italy methoxetamine is addressed by Ministerial Decree of 24 October 2012. In 
Slovenia methoxetamine was included by the Decree amending the Decree on 
classification of illicit drugs, Official Gazette of RS No. 62/2013. In Sweden 
methoxetamine comes under the Narcotic drugs control Act (SFS 1992-860) and the 
Narcotic drugs control Ordinance (SFS 1994:1554). In the United Kingdom 
methoxetamine is controlled under the Misuse of Drugs Act 1971. In Turkey 
methoxetamine is listed in the Law on Control of Narcotics no. 2313. 
Six Member States (Austria, Hungary, Poland, Portugal, Romania and Slovakia) 
reported that methoxetamine is controlled under legislation prohibiting the 
unauthorised supply of defined or qualifying new psychoactive substances. In Austria 
methoxetamine is listed as controlled by the New Psychoactive Substances Act. In 
Hungary methoxetamine is listed in Schedule C of Government Decree 66/2012. In 
Poland, methoxetamine falls under the definition of a “substitution drug” under the 
Act amending the Act on counteracting drug addiction and the Act on State Sanitary 
Inspection, 2010 and as such its marketing and production is penalized with a fine 
(administrative sanctions). In Portugal, methoxetamine is listed as controlled under 
Decree-Law 54/2013. In Romania the Law 194/2011 subjects to control any 
psychoactive substance that qualifies by conforming to certain criteria (all substances 
with psychoactive potential are subject to control until proven harmless by a special 
designated commission). In Slovakia, methoxetamine is in the List of risk substances 
 
(18)  Gas chromatography-mass spectrometry 
(19)  Nuclear magnetic resonance spectroscopy 
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published in a Ministry of Health Regulation No 298/2013 Coll., which came into force 
on 1 October 2013.  
Two Member States (Finland and the Netherlands) and Norway reported that 
methoxetamine is subject to control measures under medicines legislation. In Finland 
methoxetamine has been controlled under the Medicines Act (395/87) since 9 
December 2011. In the Netherlands, the sale of methoxetamine in consumer 
amounts it is treated as being a medicinal product and must comply with medicines 
legislation (and general product safety legislation). In Norway, methoxetamine is 
regulated by the Medicines Act and a prescription would be required to receive it. 
Eleven Member States (Belgium, Bulgaria, Croatia, Czech Republic, Estonia, 
Greece, Ireland, Lithuania, Luxembourg, Latvia and Malta) reported that 
methoxetamine is not subject to control measures. 
No information was provided regarding the control status of methoxetamine in Spain. 
3.8 Further information — Article 5.2(h) of the Decision 
3.8.1 The chemical precursors that are known to have been used for the 
manufacture of the substance 
 
No information was reported about the chemical precursors or manufacturing 
methods used to make methoxetamine. 
 
Methods for the production of methoxetamine are documented in the scientific 
literature. 
3.8.2 The mode and scope of the established or expected use of the new 
substance 
 
Methoxetamine has been marketed and sold through online shops as a legal and 
‘bladder friendly’ alternative to ketamine (Beaumont-Thomas, 2012; EMCDDA, 2011; 
Miller, 2012; Morris, 2011; Google, 2013a,b) both as branded ‘legal highs’ (Wood et 
al., 2012) as well as a ‘research chemical’. It is important to note in this respect that 
information from the Member States (such as seizures, collected samples, non-fatal 
intoxications) and user websites suggest that methoxetamine may be commonly sold 
as a ‘legal’ replacement for ketamine or sold as ketamine directly on the illicit drug 
market (20). As a result, the mode and scope of use of methoxetamine may, in part, 
overlap and/or reflect the mode and scope of use of ketamine. Additional research is 
required in order to examine to what extent, if any, the mode and scope of 
methoxetamine use overlap and/or reflect those of ketamine. 
Settings of use 
 
(20)  Along with ketamine, methoxetamine has also been sold as controlled substances such as 
MDMA and amphetamine. 
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The online 2012 Global Drug Survey that was conducted in November 2011 reported 
that out of 7700 respondents from the United Kingdom, 4.2% reported using 
methoxetamine in the last year (6% of clubbers and 3% of non-clubbers) and 2.4% 
reported using methoxetamine in the previous month (4% of clubbers and 1% of non-
clubbers). Wood et al., (2012c) in their study of use of novel psychoactive 
substances by patrons of gay friendly night clubs in South London reported that 1.6% 
of individuals reported use of methoxetamine on the night of the survey or planned to 
use it later that night. Six of the non-fatal intoxications reported by Italy noted that use 
of methoxetamine was in the context of dance or rave parties. Details from case 
series in the literature also suggest use in the night-time environment (Wood et al., 
2012c) as well as in the home environment (Westwell et al., 2012; Wood et al., 
2012c). 
Price 
Internet monitoring of the surface web conducted by the EMCDDA identified 14 
online shops offering methoxetamine in January 2011, 58 in July 2011, and 68 in 
January 2012. The price in 2011 for 10 g ranged from 145 to 195EUR (EMCDDA, 
2011; EMCCDA, 2012). It is important to note that the online sale of methoxetamine 
may have changed substantially between January 2012 and the time of writing the 
Joint Report in December 2013. In part this may reflect responses of retailers to 
national control measures that have been put in place in some countries. A search of 
google.com using the search string “buy "methoxetamine" OR “mxe"" conducted in 
December 2013 for the Joint Report identified a number of online shops offering 
methoxetamine for sale in both retail and wholesale quantities (Google, 2013c). 
3.8.3 Other use of the new psychoactive substance and the extent of such 
use, the risks associated with this use of the new psychoactive 
substance, including the health and social risks 
No information was provided by the Member States, Norway or Turkey that indicated 
that methoxetamine had any other use apart from in legitimate scientific research and 
as an analytical reference standard. 
 
From the available information it does not appear that methoxetamine is used in the 
manufacture of a medicinal product in the European Union. However, the collection 
of information cannot be considered exhaustive in the absence of an European Union 
database on the synthetic routes of all medicinal products (21). 
 
(21) i.e. products that have been granted a marketing authorisation, or where an application for a 
marketing authorisation has been made, or where the marketing authorisation has been 
suspended. 
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4. Information from the EMA as requested by Article 5.3 of the Decision 
4.1 Marketing authorisation 
Twenty-four Member States, Norway and Iceland responded to the EMA’s 
information request (see section 2) reported that the new psychoactive substance 
methoxetamine has not obtained a marketing authorisation (22).The EMA also 
reported that the new psychoactive substance methoxetamine has not obtained a 
marketing authorisation through the central authorisation procedure. 
4.2 Application for a marketing authorisation 
Twenty-four Member States, Norway and Iceland responded to the EMA’s 
information request (see section 2) reported that the new psychoactive substance 
methoxetamine is not the subject of an application for a marketing authorisation (22). 
The EMA also reported that the new psychoactive substance methoxetamine is not 
the subject of an application for a marketing authorisation through the central 
authorisation procedure. 
4.3 Suspended marketing authorisation 
Twenty-four Member States, Norway and Iceland responded to the EMA’s 
information request (see section 2) reported that there had been no cases of a 
suspended marketing authorisation that had been granted in respect of the new 
psychoactive substance methoxetamine (22). The EMA also reported that the new 
psychoactive substance methoxetamine is not the subject of a suspended marketing 
authorisation through the central authorisation procedure. 
5. Conclusion 
Methoxetamine is an arylcyclohexamine, closely related in many respects to 
ketamine. It has been available on the European Union drug market since at least 
September 2010 and has been detected in 22 Member States, Turkey and Norway. 
Multi-kilogram quantities of the substance in powder form have been seized. One 
hundred and ten non-fatal intoxications and 20 deaths associated with the substance 
have been reported. As methoxetamine is marketed as a legal and 'bladder-friendly' 
alternative to ketamine and at the same time being sold directly on the illicit drug 
market as ketamine, a key concern is that these may play a role in the further spread 
of the substance. We conclude that the health and social risks caused by the 
manufacture, trafficking and use of methoxetamine, as well as the involvement of 
 
(22) Austria, Belgium, Croatia, Czech Republic, Denmark, Estonia, Germany, Greece, Hungary, 
Iceland, Ireland, Netherlands, Norway, Portugal, Slovenia, Spain, Sweden and the United 
Kingdom provided responses in relation to both human and veterinary medicinal products. 
Cyprus, Italy, Lithuania, Malta and Slovakia provided responses in relation to human medicinal 
products. France, Latvia and Poland provided responses in relation to veterinary medicinal 
products. In addition the EMA provided information in relation to both human and veterinary 
medicinal products in respect to the central authorisation procedure. 
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organised crime and possible consequences of control measures, could be 
thoroughly assessed through a risk assessment procedure in accordance with Article 
6 of Council Decision 2005/387/JHA. 
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Annex 1 
 
 
EMCDDA–Europol Joint Report 
on a new psychoactive substance: Methoxetamine 
 
 
Images of Methoxetamine from seizures and collected samples 
 
 
Country Image Description 
 
Croatia 
 
 
 
 
Seizure, February 2012 
4 green tablets. 
Seizing authority: police 
 
 
Hungary 
 
 
 
 
Seizure, April 2011 
2 white tablets, seized in Pest county. 
Contents: Methoxetamine, 4-FMC and MDPV 
Seizing authority: police 
 
 
Italy 
 
 
 
Seizure, 2011 
6,713g of white powder contained in 1 polyethylene 
bag, seized in Como province. 
Seizing authority: police 
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Annex 2 — Deaths and non-fatal intoxications associated with methoxetamine 
Deaths 
 Country  Date of 
death 
(gender, 
age) 
Biological 
sample 
Methoxetamine 
result 
Results for other substances Notes  
1 Austria Aug 2012 Not reported + None reported Cause of death reported as central 
circulatory failure due to 
methoxetamine overdose 
2 Finland Aug 2012 Blood 5200 mg/mL Olanzapine (0.24 mg/L) 
Citalopram (0.20 mg/L) 
Clozapine (0.13 mg/L) 
Death by drowning. Medico-legal 
status not determined 
3 France Feb 2013  
(M, 38) 
Blood 9.48 µg/mL Benzodiazepines (from hospital 
treatment) 
Found dead at home. Cause of death 
reported as asphyxia 
4 Poland Jul 2012 
(M, 31) 
Blood 
Urine 
Hair 
0.32 µg/mL 
4.36 µg/mL 
Negative 
Amphetamine (0.06 µg/ml in blood, 
0.27 µg/ml in urine and  
0.19 µg/g in hair) 
Cause of death reported as acute 
poisoning as a result of 
methoxetamine and amphetamine. 
5 Sweden Feb 2012 Femoral 
blood 
8.6 µg/g AM-694 (+) 
AM-2201 (+) 
JWH-018 (+) 
cannabis (+) 
venlafaxine (+) 
The cause of death reported as 
suspected acute intoxication with 
methoxetamine although the presence 
of the three synthetic cannabinoids 
may have contributed to the death. 
6 United 
Kingdom 
Aug 2011 
(M, 29) 
Blood + Methadone (645µg/L EDDP in blood, 
also present in urine) and mirtazepine 
(69 µg/L in blood, also present in 
urine) 
Cause of death was reported as drug 
overdose 
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 Country  Date of 
death 
(gender, 
age) 
Biological 
sample 
Methoxetamine 
result 
Results for other substances Notes  
7 United 
Kingdom 
2011 (month 
not 
specified) 
Blood + Fluoromethcathinone (+) 
MDMA (+) 
Methylone (+) 
MDAI (+) 
MDPV (+) 
5-IAI (+) 
AMT (+) 
Deceased was found decomposed at 
home 
8 United 
Kingdom 
Jan 2012 
(M, 25) 
Blood, urine 
& vitreous 
humour 
+ Alcohol (80 mg/100 ml in blood, 146 
mg/100 mL in urine, 155 mg/100 mL in 
vitreous humour) and dihydrocodeine 
(+) 
Cause of death was reported as 
drowning, with methoxetamine 
ingestion noted as a contributory 
factor.  
9 United 
Kingdom 
Jan 2012 
(M, 17) 
Blood, urine 
& vitreous 
humour 
+ Alcohol (80 mg/100 ml in blood, 146 
mg/100 mL in urine, 109 mg/100 mL in 
vitreous humour) 
Cause of death was reported as 
drowning, with methoxetamine 
ingestion noted as a contributory 
factor. 
10 United 
Kingdom 
Jan 2012 
(M, 43) 
Blood 0.89 mg/L 
(unpreserved) 1.1 
mg/L (preserved) 
Methiopropamine (2.8 mg/L in 
unpreserved blood) 
Case of death was reported as 
methoxetamine and methypropamine 
toxicity [sic] 
11 United 
Kingdom 
Mar 2012  
(M, 20) 
Not reported 0.22 mg/L None reported Cause of death was reported as 
drowning 
12 United 
Kingdom 
Sep 2012 
(F, 27) 
Blood + 6-APB (2460 ng/mL) Case of death was reported as 
ingestion of 6-APB (benzofury) and 
methoxetamine 
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 Country  Date of 
death 
(gender, 
age) 
Biological 
sample 
Methoxetamine 
result 
Results for other substances Notes  
13 United 
Kingdom 
Sep 2012 
(M, 41) 
Blood & urine +  
(in urine) 
Methiopropamine (1.74 mg/L in blood 
and present in urine),  
MDA (0.18 mg/L in blood and present 
in urine) and  
Alcohol (7 mg/100 ml in blood and 16 
mg/100ml in urine) 
Cause of death was reported as natural 
causes (ischaemic heart disease and 
coronary artery atheroma) 
14-
19 
United 
Kingdom 
2012 
(months 
unspecified) 
Not reported + None reported 6 deaths 
20 United 
Kingdom 
Jan 2013 
(M, 27) 
Blood, urine, 
gastric and 
nasal swabs 
0.03 mg/L in 
blood, present in 
gastric and nasal 
swab samples 
Amitriptyline (0.13 mg/L in blood and 
present in gastric sample) 
Cocaine (0.44 mg/L in blood and 
present on nasal swabs) 
Diazepam (4.27 mg/l in blood, 9 mg in 
gastric sample) and metabolites 
MDMA (0.20 mg/L in blood, 3 mg in 
gastric sample and present on nasal 
swabs) 
MDA (present in blood) 
Case of death was reported as mixed 
drug toxicity 
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Non-fatal intoxications 
Country Date of death 
(gender, age) 
Biological 
sample 
Methoxetamine 
results 
Results for other substances Notes 
Belgium Oct 2013 
 
Urine + Not detected Powder (confirmed to contain methoxetamine) marketed as 
‘Special K’. 
Most prominent symptoms: euphoria, hallucinations and 
dissociation. Supportive and symptomatic treatment. 
France Dec 2011 
 
Blood and 
urine 
30µg/L (plasma) 
408µg/L (urine) 
Negative No further details reported. 
France Jun 2012 Hair + Not reported No further details reported. 
France 2012 Blood 136ng/mL Cannabis (+) 
Paracetamol (+) 
No further details reported. 
Italy Feb 2012 
(M, 27) 
Blood and 
urine 
0.0002 mg/mL  
(serum) 
0.167 mg/mL  
(urine) 
Methorphan  (present in urine) Powder, nasally insufflated. 
At admission to hospital the patient was tachycardic (HR 120 
bpm), confused, hallucinated and severely agitated. Treatment: 
IV diazepam; the day after admission, a treatment with 
midazolam 15 mg/day, delorazepam 7 mg/day and valproic acid 
400 mg/day was started: subsequently, the delorazepam dosage 
was increased up to 20 mg/day and haloperidol was added. 
Italy Jun 2012 
(M, 38) 
Blood and 
urine 
167 ng/mL 
(blood) 
7400 ng/mL  
(urine) 
APB-isomers (164 ng/mL) 
Amphetamines (+) 
MDMA (traces) 
A man coming from a rave was admitted to the emergency room 
accompanied by the police in a serious state of agitation and 
violent behavior. At admission the patient was mydriatic, 
stuporous (sometimes catatonic), normothermic (T 36°C), 
hypertensive (150/90 mmHg) and normo-frequent (78 bpm). The 
blood alcohol content, performed on site, was found to be 2.3 
g/L. The patient was treated with fluids and has left against 
medical advice after about 8 hours of observation. 
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Country Date of death 
(gender, age) 
Biological 
sample 
Methoxetamine 
results 
Results for other substances Notes 
Italy Jul 2012 
(M, 17) 
Blood and 
urine 
198 ng/mL 
(blood) 
9000 ng/ml  
(urine) 
Amphetamine (1000 ng/mL) 
MDMA (500 ng/mL) 
THC (141 ng/mL) 
Ketamine/norketamine (+) 
MDA (+) 
Severe psychomotor agitation status associated with 
hallucinations. Acute intoxication. 
Italy Oct 2012 
(M, 24) 
Urine + Alcohol (2.7 g/L) 
Methadone (+) 
Cocaine (+) 
Amphetamines (+) 
MDMA (+). 
APB-isomers (+) 
Levamisole (+) 
Severe agitation associated with stupor, mydriasis, slight rise in 
blood pressure (130/80 mmHg) and significant tachycardia (150 
bpm) without hyperthermia. The patient left the hospital 
voluntarily after 8 hours of observation. 
Italy Oct 2012 
(M, 23) 
Urine + THC 
Cocaine (+) 
Opiates (+) 
Levamisole (+) 
Intoxication after the consumption of ‘3 red cylinders’ and alcohol. 
The patient was rescued in confused state.  At admission to the 
emergency room the patient was slowed, sometimes somnolent, 
normothermic, normotensive and normo-frequent, without 
abnormal rhythms of the ECG. 
Italy Nov 2012 
(M, 23) 
Urine + Alcohol (2.2 g/L in blood) 
THC (+) 
Ketamine and norketamine (+) 
At admission to the emergency room the patient was in coma, 
with normal vital parameters except for peripheral oxygen 
saturation (Sat O2 90%). 
Italy Nov 2012 
(M, 22) 
Urine + THC (+) 
Ketamine and norketamine (+) 
At admission to the emergency room the patient presented 
mydriasis and severe psychomotor agitation associated with 
hallucinations/dissociative state. 
Italy Nov 2012 
(F, 16) 
Urine + THC (+) At admission to the emergency room the patient was confused, 
agitated and sometimes amnesic for the events that happened 
during the night. 
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Country Date of death 
(gender, age) 
Biological 
sample 
Methoxetamine 
results 
Results for other substances Notes 
Italy Nov 2012 
(F, 17) 
Urine + THC (+) 
Ketamine and norketamine (+) 
At admission to the emergency room the patient appeared miotic, 
confused, disoriented, agitated and sometimes amnesic for the 
events that happened during the night. 
Italy Jan 2013 
(F, 22) 
Urine + Cocaine (+) 
Opiates (+) 
Buprenorphine (+) 
Levamisole (+) 
At admission to the emergency room, the  patient was 
unresponsive, with response to painful stimuli, with open eyes 
and pupils of medium size reactive to light, with no signs of 
venipuncture, normothermic, BP of 140/100 mmHg, mild 
tachycardia (100 bpm) with no other alterations of the rhythm. 
Italy Jan 2013 
(M, 23) 
Urine + Amphetamine (+) 
Cocaine (+) 
MDMA (+) 
Levamisole (+) 
At admission to the emergency department, the patient was 
unresponsive, with eyes open and pupils of medium size and 
reactive to light, vertical nystagmus, somnolent, normothermic, 
with normal blood pressure, heart rate of 98 bpm with no other 
abnormal rhythms. There was alcohol halitosis. The patient was 
treated with naloxone, leading to slight clinical improvement. 
Blood tests showed slightly elevated CPK (390 IU/L). 
Italy Feb 2013 
(F, 22) 
Urine + Negative Sniffing 
At admission to the emergency department the patient was 
awake, lucid, and referred chest pain, diffuse pain sensation and 
tremors. 
Sweden Mar 2011 – 
Oct 2012 
Blood and 
Urine 
+ None 11 cases. 
Symptoms were hypertension (36%), tachycardia (36%), 
hallucinations (27%), nystagmus (27%), CNS-depression (27%), 
mydriasis (27%), anxiety (18%), muscular symptoms (18%), 
agitation/restlessness (9%) 
Poisoning severity scores were mild (7 cases), moderate (2) and 
severe (2). 
See Östberg et al., (2011) for further details. 
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Country Date of death 
(gender, age) 
Biological 
sample 
Methoxetamine 
results 
Results for other substances Notes 
Sweden Mar 2011 – 
Oct 2012 
Blood and 
Urine 
+ 5-IT (23) (+) 
Amphetamine (+) 
Benzodiazepines (+) 
Buprenorphine (+) 
Ethanol (+) 
MDPV (+) 
Morphine (+) 
4-OHMET (24) (+) 
Cannabis/THC (+) 
Tramadol (+) 
27 cases.  
Symptoms were hypertension (48%), CNS-depression (44%), 
tachycardia (44%), agitation/restlessness (33%), mydriasis 
(30%), nystagmus (26%), hallucinations (22%), anxiety (19%) 
and muscular symptoms (11%) 
Poisoning severity scores were mild (11 cases), moderate (10), 
severe (3) and unknown (3). 
The results for other substances detected were not provided for 
each case. See Östberg et al., (2011) for further details. 
 
 
 
(23) 5-(2-Aminopropyl)indole 
(24) 4-Hydroxy-methylethyltryptamine 
